By :- Subhi Sharma
Diabetes MELLITUS IS THE THIRD LARGEST KILLING DISEASE NOW A DAYS .After cancer and cardiovascular diseases……..some herbal advancement such as momordica indica,termanalia chebula have known to reduce blood sugar but a new aid has been discovered by Novo Nordisk, Its an ultra long acting insulin named as Insulin Degludec over long acting Insulin glargine. (forms soluble multihexamer assemblies after subcutaneous injection) However with some disadvantages of this insulin as that it cannot be mixed with any other insulin preparation because it is not suitable at acidic pH…and also does not control meal time glycaemia.It is injected subcutaneously three-times a week to help control the blood sugar level of those with diabetes. Its advantage is that it has a duration of action that lasts up to 40 hours, unlike the 18 to 26 hours provided by current marketed long-acting insulins such as Insulin glargine and Insulin detemir.
Studies have shown that patients taking insulin degludec needed to take significantly smaller doses of basal insulin than those taking insulin glargine, while achieving similar blood glucose levels. Insulin degludec also has the ability to be mixed with other insulins, something that cannot be done using current long-acting insulins.
Insulin degludec is currently in Phase III clinical trials, the final step before regulatory filing in the United States. Novo Nordisk hopes to begin marketing the novel insulin analog in 2013.
Here is a link in regards to this [updated on 24th June]
Ultra-long-acting insulin degludec, under development, lowers blood glucose levels with significantly reduced rates of hypoglycaemia (low blood sugar) compared to insulin glargine, according to data presented at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego. Data were from two, phase three, 52-week clinical trials, one individuals with type 1 and one individuals with type 2 diabetes.
Separately, in a late-breaking presentation, data revealed that insulin degludec could be dosed at different times from day to day in a 26-week trial.
“Episodes of low blood sugar, known as hypoglycaemia, are a major concern for many people with diabetes,” said Alan Garber, MD, Professor, Departments of Medicine, Baylor College of Medicine, in Houston, Texas, USA. “It is particularly encouraging that insulin degludec significantly reduces the rate of overall hypoglycaemia in type 2 patients and nocturnal hypoglycaemia, in patients with type 1 or type 2 diabetes. The findings of these studies suggest that insulin degludec potentially offers substantial benefits for patients and the management of their diabetes.”
Trials were ‘treat-to-target’ studies, meaning insulin was titrated systematically to achieve a target fasting glucose level. Patients in the open-label trials, using insulin degludec and insulin glargine had similar starting glucose levels, allowing researchers to closely determine the differences between the treatments.